FVIII-GMAC

Hemophilia A

PreclinicalNon-clinical studies ongoing

Key Facts

Indication

Hemophilia A

Phase

Preclinical

Status

Non-clinical studies ongoing

Company

Japanese biotech developing one-time ex-vivo gene therapies using genetically modified human adipocytes for rare genetic diseases.

Drug	Company	Phase	Status
GS1191	Gritgen Therapeutics	Phase 1	Active
BIVV001 (rFVIIIFc-VWF-XTEN)	Swedish Orphan Biovitrum	Phase 3	Active
Coagulation Factor VIII	Shanghai RAAS Blood Products	Marketed	Active
Human Coagulation Factor VIII	Hualan Biological Engineering	Marketed	Approved
Giroctocogene fitelparvovec (SB-525)	Sangamo Therapeutics	Phase 3	Active, Not Recruiting